Long-term activation of the STING pathway in the liver aggravates inflammation, hepatocyte death, and compensatory proliferation, thereby promoting the inflammation-driven carcinogenesis pathway, suggesting that the inhibition of STING appears to be a potential strategy to slow the progression of inflammatory NASH. Here, STING1 is linked to metabolic dysfunction-associated steatohepatitis.